A Pilot Study Using a Randomized Design to Evaluate the Immunologic Efficacy and Safety of ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors
Phase: PHASE4
Conditions: Shingles
Sponsor: Louis Stokes VA Medical Center

Cover sheet 
 
Most recent IRB approved protocol 
 
4-13-17 
 
Title: ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors 
 
NCT02444936 
 
PI: David H. Canaday, MD 
Cleveland VA 

IRB #: \Ltl)Lft,[, tcl,"C"l 
(Assigned by IRE Office) 
. r\ i2J nL\. 
CPA#: 
Jl' 
-- 
(Assigned by IRE Office) 
AP,rov
1
ed
41 /J 11 
Cleveland
r
VAMC 
Institutional Review Board 
Form Directions: Form is protected (user has limited access to the fill-infields). Use the tab key or mouse to navigate the fill-in 
fields. Formatting is limited in the text fields (no bulleted lists, numbering, etc). In the event that the user is unable to navigate 
through the protected document or would like to format a document, the user can disable the ''protected" feature (select "Review" 
then "Restrict Ending" then "Stop Protection"). Please do not delete or modify questions .. 
Louis Stokes Cleveland Department of Veterans Affairs Medical Center 
Research Plan 
Please contact the IRB office if you have any questions at (216) 791-3800 ext. 4658. 
D Request for Expedited IRB Review Form attached 
Human Subject Research: Human subject research means research involving interaction or .intervention with 
living human beings or access to identifiable private information ofliving human beings. 
Research Plan: The information requested in the Research Plan is designed to provide the IRB with the necessary 
information such that it can make the federally required determinations codified at 38 CFR Part_ 16, 21 CFR Parts 
50, 54, & 56, and 45 CFR Part 46 
The Research Plan is to be written so that the non-scientist/non-medical members of the !RB can understand the 
research proposed. Define all abbreviations and terms that are not part of common language. 
Version Date: This should be updated subsequently with every modification to any part of the Research Plan. Any 
modification to this document, no matter how minor, must be reviewed and approved by the !RB prior to 
implementation. The Research Plan will be stamped with the date of!RB approval 
1. Version Date: 3-23-17
2. Title of Project: Shingles vaccine in oncology patients .
3. Principal Investigator (PI) (name & degrees): David Canaday, MD
E-mail: dxc44@case.edu
Pager Number/Cell Phone Number: 216-368-8901 UH pager 35324 
4. Research Contact/Research Coordinator (name, degrees): Richard Banks
E-mail: Richard.banks2@va.gov
Pager Number/Cell Phone Number: ext 6032 
LSCDVAMC 
April 2014 
Research Plan 
Page 1 of 29